INTRODUCTION

Flea-borne typhus, also known as endemic or murine typhus, is a rickettsial zoonosis caused by *Rickettsia typhi* that occurs predominantly in warm, coastal areas of the world, including certain parts of the United States. During the early 1940s, approximately 2,000–5,000 cases were reported annually, but sanitation and vector control campaigns significantly reduced the number of flea-borne typhus cases in the United States. In 1995, flea-borne typhus was removed from the list of nationally notifiable diseases, making the contemporary prevalence of flea-borne typhus in the United States difficult to ascertain; nonetheless, flea-borne typhus remains a reportable disease in 14 U.S. states (CA, HI, IL, IN, MI, MN, MS, NE, NH, OH, OR, PA, TX, and WA). The majority of U.S. cases occur in Texas, which reported 3,048 confirmed or probable cases of flea-borne typhus during 1985–2015 (Texas Department of State Health Services, unpublished data). Flea-borne typhus is often described as a relatively mild and self-limiting rickettsiosis; nonetheless, a spectrum of severe manifestations is also recognized, and the disease may be fatal in as many as 5% of patients for whom appropriate antibiotic therapy is delayed or not provided. The objective of this study was to describe the clinical and epidemiologic features associated with fatal flea-borne typhus cases in Texas.

METHODS

Flea-borne typhus cases are reported in Texas by using a standardized case report form that includes demographic information, various clinical characteristics, duration of illness, animal and arthropod exposure, travel history, and outdoor activities prior to illness onset. The data were reviewed for confirmed and probable fatal cases identified during 1985–2015. When available, medical charts were examined for supplemental information relating to comorbidities, clinical presentation, antibiotic therapy, laboratory results, and diagnosis at time of death. Diagnostic test results were generated by multiple commercial laboratories or by state or national reference centers. All personally identifiable information was removed from the case investigation forms and medical charts before review at the Centers for Disease Control and Prevention (CDC). This case series protocol was reviewed and determined to qualify as non-research and was exempt from further review according to the CDC’s National Center for Emerging and Zoonotic Infectious Diseases institutional procedures.

A confirmed case was defined as a patient with a clinically compatible illness and 1) a 4-fold or greater rise in antibody titer to *R. typhi* antigens by using an indirect immunofluorescence antibody (IFA) assay in acute and convalescent phase serum specimens; or 2) a single reciprocal IFA titer ≥ 1:024; or 3) a positive polymerase chain reaction (PCR) assay to *R. typhi*; or 4) demonstration of typhus group *Rickettsia* sp. antigens by an immunohistochecmical stain in tissue; or 5) isolation of *R. typhi* from clinical specimen. A probable case was defined as a patient with a clinically compatible illness and a reciprocal IgG or IgM IFA titer of ≥ 64.

RESULTS

Eleven confirmed or probable fatal cases of flea-borne typhus were reported in Texas during 1985–2015 (Figure 1). The median age of the patients was 62 years (range, 36–84 years) and 9 (82%) were > 50 years of age. Eight (73%) patients were male and seven (64%) were of Hispanic ethnicity.
(Table 1). Six patients met the criteria for a confirmed case; four (67%) patients were diagnosed with single reciprocal IFA titers $\geq 1,024$ (range, 1,024–4,096); one patient demonstrated a 4-fold rise in antibody titer; one patient had a skin biopsy specimen that stained positive for antigens of a typhus group *Rickettsia* sp. (Figure 2) and a reciprocal IFA titer of $\geq 4,096$ (Table 1). Five patients met the criteria for a probable case and were classified using a reciprocal serologic titer $< 1,024$ (range, 64–512). Of these, one had reciprocal IgG and IgM titers of 256 and 2,048, respectively, 5 days post-onset, and one had reciprocal IgG and IgM titers of 64 and 512, respectively, 9 days after illness onset (Table 1). No patients were diagnosed by PCR or culture isolation. Five (38%) patients were additionally tested by an IFA assay using antigens of *Rickettsia rickettsii* (the agent of Rocky Mountain spotted fever [RMSF]); 2(40%), 1(20%), and 2(40%) had reciprocal IgG antibody titers to this antigen at $\geq 64$, 128, and 512, respectively. Both patients with *R. rickettsii* titer of 512 had *R. typhi* titers $\geq 4,096$. For the patients with reciprocal titers to both rickettsial antigens, the titer to *R. typhi* was consistently 4-fold or greater than the titer to *R. rickettsii*. Two additional patients were identified in 1999 and 2001. These patients each had reciprocal IgG antibody titers to *R. typhi* of 512; however, no additional case information was available on their clinical course of illness and they were excluded from further analysis.

Eight of 11 (73%) case report forms contained information on flea or animal contact in the 2 weeks before illness onset. Three (27%) patients reported fleas in the home, three (27%) patients had at least one dog, and four (36%) patients either owned a cat or cared for stray cats. Two (18%) patients reported an opossum living within or next to their home (Table 1). One (9%) patient reported hunting in south Texas before illness onset, but no specific animal species were named. Cases occurred year-round with no apparent seasonality (Table 1).

All patients were hospitalized. At hospital presentation, fever was reported for 11 (100%) patients. The median temperature was 101.9°F (range, 99–104.6°F). Thrombocytopenia (82%) and elevated hepatic transaminase levels (64%) were the most frequently reported laboratory abnormalities. Six (55%) patients reported one or more respiratory-related symptom (i.e., cough), or diagnosis (i.e., pneumonia, pulmonary edema, or acute respiratory distress syndrome). Rash was reported in 55% of patients, and was described as macular and maculopapular (50%) or petechial (50%), and was distributed across the palms and soles (33%), arms and legs (33%), and trunk (67%) (Table 2). Rash was frequently reported as a late finding, occurring > 7 days after initial illness onset.

The median time from symptom onset to hospitalization was 8 days (range, 1–21 days), and the median time from symptom onset to death was 14 days (range, 1–34 days). Four (36%) patients sought medical care during their first week of illness; two cases were diagnosed with urinary tract infections unrelated to *R. typhi* infection and prescribed non-tetracycline class antibiotics, one patient received an unknown antibiotic for an unspecified illness, and the fourth patient had no information available. Two (18%) patients received a sulfam-containing antibiotic during their illness.

Seven (64%) patients received a tetracycline-class antibiotic (doxycycline or tetracycline) during hospitalization. The median number of days from hospital admission to initiation of a tetracycline-class antibiotic was 4 (range, 0–5 days). The median time from symptom onset to initiation of a tetracycline-class drug was 9 days (range, 4–17 days).

Additional data abstracted from medical charts were available for eight patients. Of these, neurologic complications were present at hospital admission in five (63%) patients and included meningitis, encephalitis, vertigo, dizziness, seizure, and coma. Two of the five patients were obtunded on presentation and never regained consciousness. At hospital presentation, two (25%) patients had acute kidney injury. Comorbidities were for five (63%) of these patients including three (37%) with a history of alcohol abuse, one (13%) with chronic renal disease, congestive heart failure, and Type 2 diabetes mellitus, and one (13%) with a preexisting seizure disorder.

**DISCUSSION**

To our knowledge, this is the largest series of patients with fatal flea-borne typhus. The case fatality rate (CFR) in Texas during this period (0.4%) was not significantly different from the CFR described for 200 cases of flea-borne typhus from Texas that occurred during 1980–198412 (1%, $P = 0.30$). During the pre-antibiotic era, CFRs of flea-borne typhus varied regionally, but the overall CFR for

---

**TABLE 1**

| Patient (age/sex) | Ethnicity | Animal exposure | Flea exposure | Onset (month/year) | Days from onset to death | Case status | Reciprocal IgG IFA titer(s) to *Rickettsia typhi* |
|------------------|-----------|----------------|--------------|--------------------|--------------------------|------------|--------------------------------------|
| 81/F             | Hispanic  | Yes†           | Unknown      | June 1985          | 11                       | Confirmed  | 64, 1,024†                           |
| 67/M             | Non-Hispanic | No             | No           | September 1986     | 17                       | Probable   | 256                                  |
| 36/M             | Hispanic  | Unknown        | Unknown      | June 1991           | 8                        | Confirmed  | $\geq 1,024$                         |
| 72/M             | Hispanic  | Unknown        | Unknown      | June 1995           | 34                       | Confirmed  | $\geq 1,024$                         |
| 73/F             | Hispanic  | Yes†           | Yes          | December 1998      | 6                        | Probable   | 512§                                 |
| 53/M             | Hispanic  | Unknown        | Unknown      | January 2007        | 6                        | Confirmed  | $\geq 1,024$                         |
| 36/M             | Non-Hispanic | Yes†           | Yes          | April 2012          | 13                       | Confirmed  | $\geq 4,096$                         |
| 50/M             | Non-Hispanic | Yes†           | Unknown      | May 2013            | 20                       | Confirmed  | $\geq 4,096¶$                       |
| 55/M             | Hispanic  | Yes†           | Yes          | May 2013            | 14                       | Probable   | 256                                  |
| 84/F             | Hispanic  | Unknown        | Unknown      | November 2014       | 12                       | Probable   | 64||                                 |
| 62/M             | Unknown   | Yes†           | Unknown      | January 2015        | 9                        | Probable   | 256**                                |

1 IFA = indirect immunofluorescence antibody.
2 Reported exposure to: * opossum, fcat, § dog.
3 Patient also had 1:40 titer to *R. typhi* by slide agglutination assay.
4 Patient also had a skin biopsy specimen positive for a typhus group *Rickettsia* sp. by immunohistochemical stain.
5 Patient also had a reciprocal IgM IFA titer of 512 on same date.
6 Patient also had a reciprocal IgM IFA titer of 2,048 on same date.
18,337 U.S. cases during 1940–1944 was 4.6%. Among the cases reviewed herein, a high proportion were male (73%) and over the age of 50 years (82%). More than 70% of the patients in this series who were treated with a tetracycline-class antibiotic did not receive this drug until the second week of illness, emphasizing the need for prompt administration of appropriate antimicrobial therapy to reduce fatal outcome.

Respiratory signs or symptoms were noted for more than half of the patients in this series. The frequency of respiratory manifestations have been recognized for many years; indeed, an early summary of flea-borne typhus in Texas noted, “few diseases present so much subjective respiratory symptoms with so little objective findings.” Previous literature reported 14–59% of flea-borne typhus patients had respiratory symptoms. Neurologic manifestations
were also seen in more than half of the patients for whom additional data were available, and previous literature has described neurologic manifestations in 15–45% of patients.17,18 Our findings are consistent with previous literature and suggest that respiratory and neurologic complications from R. typhi infection may occur frequently in severe cases.6,16,18–21 The frequency of respiratory and neurologic manifestations identified in this series may have been confounded by the advanced stage of disease that patients presented at initial hospital presentation. Previous literature reports risk of complications increases with age. Therefore, older patients (> 50 years) may be at greater risk for poor outcomes.20,22,23

Of the seven patients with elevated hepatic transaminases, three (43%) had a history of alcohol abuse. Clinicians may have attributed elevated hepatic transaminases to complications from alcohol abuse; however, hepatic inflammation has also been documented with severe flea-borne typhus.24,25 Two patients in this case series were treated with sulfa-containing antibiotic after illness onset and before hospital admission. Multiple historical and contemporary case reports describe adverse outcomes in flea-borne typhus patients treated with sulfa-containing antibiotics.11,18,26 Similar observations have been identified in patients with other rickettsial diseases, particularly RMSF and Ehrlichia chaffeensis ehrlichiosis.27 Case–control studies are needed to better assess the potential contraindication of sulfa drugs in the treatment of patients with rickettsiosis, including flea-borne typhus. Glucose-6-phosphate dehydrogenase deficiency was not identified or assessed as a comorbidity in any of the patients in this series; nonetheless, this condition has been previously associated with life-threatening disease in patients with flea-borne typhus28 as well as other rickettsioses including RMSF29 and Mediterranean spotted fever (caused by Rickettsia conorii)30 and scrub typhus (caused by Orientia tsutsugamushi).28

Five cases of fatal flea-borne typhus have been reported previously in detail.20,26,31 These patients, from the United States and Spain, presented with similar demographic and clinical characteristics to the patients in our case series. Their median age was 56 years (range, 46–81 years), three (60%) were male, one (20%) reported contact with rodents, four (80%) reported fever, one (20%) had rash, two (40%) had thrombocytopenia, one (20%) developed respiratory manifestations, and one (20%) developed neurologic manifestations. The median time from illness onset to death was 13 days (range, 11–15 days). Importantly, two (40%) received a sulfa-containing antibiotic.

In previous outbreaks, as many as 70% of patients of flea-borne typhus have required hospitalization and as many as 30% of these patients require admission to an intensive care unit; nonetheless, even in areas such as Texas where the disease is endemic, a correct diagnosis of flea-borne typhus is often delayed for 10 or more days.33 The signs and symptoms of even advanced disease may be nonspecific and can hamper a timely diagnosis. Delay in treatment with a tetracycline-class antibiotic is associated with poorer outcomes including death. Doxycycline is the drug of choice for treating rickettsiosis in patients of all ages.34 Flea-borne typhus should be considered in patients with a history of animal or flea exposure and a nonspecific febrile illness of > 3 days.22,31,34 Absence of rash should not exclude a presumptive diagnosis of flea-borne typhus,
particularly as it often occurs late in the development of disease, as identified in this series. A history of recent exposure to fleas or animals can provide valuable clues into potential etiology of unknown illness; however, absence of known animal or flea exposures does not rule out flea-borne typhus in an endemic area, as patients may be unaware of these exposures.

This case series had several limitations inherent to studies that use data acquired predominantly or exclusively through passive surveillance, including incompleteness of information reported to the state health department, and inability to review medical charts for some of the patients. In contrast to many other rickettsioses endemic in the United States, typhus group rickettsioses are not nationally notifiable. In that context, there are no nationally recognized laboratory criteria to define confirmed or probable cases of typhus group rickettsioses. Because each of the fatal cases were from Texas, we applied the case definitions developed by the Texas Department of State Health Services. Nonetheless, a single antibody titer is not a universally accepted laboratory criterion for a confirmed case. Furthermore, because this was a retrospective study, the serological data were generated by multiple laboratories during a 30-year period and therefore lack consistency with respect to reagents, methods, and interpretation by laboratory personnel. Finally, this study lacked a control group to comparatively assess risk factors. Future case–control studies could help identify risk factors for severe and fatal outcomes in patients with flea-borne typhus.

Infection with *Rickettsia felis*, a typhus-like *Rickettsia*, has been documented in at least one patient in Texas.\(^3^5\) Because *R. typhi* and *R. felis* occur sympatrically in fleas in Texas, it is possible that *R. felis* may be responsible for some cases of flea-borne typhus;\(^3^6–3^8\) however, vertebrates infected with *R. felis* characteristically produce antibodies that cross-react with antigens of spotted fever group rickettsiae rather than typhus group rickettsiae.\(^3^9,4^0\) Antibodies reactive with spotted fever group rickettsiae were detected in five of the patients in this series for whom these tests were performed, but each of these patients had corresponding typhus group titers that were at least 4-fold higher. Additionally, *R. typhi* typically causes more severe disease in humans than *R. felis*;\(^5,1^9,2^2\) and to our knowledge there are no reported fatal cases of human infection with *R. felis*. A previous study of Texas patients for whom a flea-borne rickettsiosis was suspected found evidence of infection with *R. typhi* in 22% versus infection with *R. felis* in only 2%, by using species-specific recombinant antigens, to suggest that infections with *R. typhi* are more prevalent in humans in Texas than are infections with *R. felis*.\(^4^1\) In this context, we believe each of the fatal cases described herein represented infection with *R. typhi* rather than *R. felis*. A confirmed human infection with *Rickettsia prowazekii*, another typhus group *Rickettsia* species, was described in 2001 that may have been acquired in south Texas\(^5^9\) and serological evidence of infection with *R. prowazekii* was confirmed by cross-adsorption assays in two of 19 home-less persons in Houston, TX, with antibodies reactive to typhus group rickettsiae.\(^4^2\) *Rickettsia prowazekii* has been detected in an *Amblyomma* tick collected in northern Mexico,\(^4^4\) and this species is also found in south Texas.\(^4^4\) In this context, it is also possible that some of the cases in this case series were caused by *R. prowazekii* rather than *R. typhi*.

Clinicians may want to consider older age, delay in treatment, and a history of alcohol abuse as potential risk factors for severe flea-borne typhus; however, case–control studies need to be conducted to identify risk factors for severe disease. Severity of disease may be mitigated by early diagnosis and initiation of appropriate tetracycline-class antibiotic therapy. Clinicians should be aware that flea-borne typhus is a potentially serious illness and should be considered in febrile patients with animal or flea exposure and respiratory or neurologic signs of unknown etiology.

Received June 10, 2016. Accepted for publication January 17, 2017.

Published online March 6, 2017.

Acknowledgments: We would like to acknowledge the contribution of the local, regional, and state public health personnel for their assistance in reporting and investigating cases of flea-borne typhus.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

Authors’ addresses: Emily G. Pieracci, Rickettsial Zoonoses Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, and Epidemic Intelligence Service, Center for Surveillance, Epidemiology and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA, E-mails: epieracci@cdc.gov, Nicole Evert, Bonny Mayes, and Inger Vilcins, Texas Department of State Health Services, Austin, TX, E-mails: nicole.evert@dshs.state.tx.us, bonny.mayes@dshs.state.tx.us, and inger.vilcins@dshs.state.tx.us. Nicole A. Drexler, Casey Barton Behravesh, and Christopher D. Paddock, Rickettsial Zoonoses Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, E-mails: ndrexler@cdc.gov, cbartonbehravesh@cdc.gov, and cpaddock@cdc.gov. Philip Huang and Jill Campbell, Austin/Travis County Health and Human Services Department, Austin, TX, E-mails: philip.huang@ austintexas.gov and jill.campbell@dshs.state.tx.us.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Azad AF, 1990. Epidemiology of murine typhus. *Annu Rev Entomol* 35: 553–569.
2. CDC, 2004. Summary of notifiable diseases—United States, 2002. *MMWR Morb Mortal Wkly Rep* 51: 74.
3. Evert N, Mayes B, 2015. *Flea-Borne Typhus in Texas (2003–2013)*. 65th James Steele Conference on Diseases in Nature Transmissible to Man, 2015. Galveston, TX, 57.
4. Boostrom A, Beier MS, Macaluso JA, Macaluso KR, Sprenger D, Hayes J, Radulovic S, Azad AF, 2002. Geographic association of *Rickettsia felis*-infected opossums with human murine typhus, Texas. *Emerg Infect Dis* 8: 549–554.
5. Whiteford SF, Taylor JS, Dumler JS, 2001. Clinical, laboratory, and epidemiologic features of murine typhus in 97 Texas children. *Arch Pediatr Adolesc Med* 155: 396–400.
6. Carr SB, Bergamo DF, Emmanuel PJ, Ferreira JA, 2014. Murine typhus as a cause of cognitive impairment: case report and a review of the literature. *Pediatr Neurol* 50: 265–268.
7. Fergie JE, Purcell K, Wanat D, 2000. Murine typhus in south Texas children. *Pediatr Infect Dis J* 19: 535–538.
8. Sakamoto N, Nakamura-Uchiyama F, Kobayashi K, Takasaki T, Ogasawara Y, Ando S, Iwabuchi S, Ohnishi K, 2013. Severe murine typhus with shock and acute respiratory failure in a...
Japanese traveler after returning from Thailand. J Travel Med 20: 50–53.

9. Dittrich R, Rattanavanong S, Lee SJ, Panyanivong P, Craig SB, Tulsiani SM, Blackside SL, Dance DA, Dubot-Peres A, Sengdualaphachan A, Phounin P, Paris DH, Newton PN, 2015. Orientia, Rickettsia, and leptospira pathogens as causes of CNS infections in Laos: a prospective study. Lancet Glob Health 3: e104–e112.

10. Adjemian J, Parks S, McElroy K, Campbell J, Eremeeva ME, Nicholson WL, McQuiston J, Taylor J, 2010. Murine typhus in Austin, Texas, USA, 2008. Emerg Infect Dis 16: 412–417.

11. Peterson JC, Overall JC, Shapiro JL, 1947. Rickettsial diseases of childhood; a clinical pathologic study of tick typhus, Rocky Mountain spotted fever and murine typhus, endemic typhus. J Pediatr 30: 495–528.

12. Miller ES, Beeson PB, 1946. Murine typhus fever. Medicine 25: 1–15.

13. Beck D, Van Allen A, 1950. Typhus Fever in California, 1916–1948. Inclusive. San Francisco, CA: State of California, Department of Public Health.

14. Joseph C, 1942. Typhus fever in Charity Hospital. New Orleans Med Surg J 95: 53–60.

15. Kemp HA, 1939. Endemic typhus fever in Texas: an epidemiological and clinical comparison with forms of typhus seen elsewhere. Am J Trop Med Hyg 81–90, 109–129.

16. van der Vaart TW, van Thiel PP, Juffermans NP, van Vugt M, 2000. Hepatitis and the distribution of Rickettsia typhi in a Netherlands population. Clin Infect Dis 20: 1575–1577.

17. Stuart BM, Pullen RL, 1945. Endemic (murine) typhus: clinical observations of 180 cases. Ann Intern Med 23: 520–536.

18. Dummer JS, Taylor JP, Walker DH, 1991. Clinical and laboratory features of murine typhus in south Texas, 1980 through 1987. JAMA 266: 1365–1370.

19. Chaliotis G, Kritsotakis EI, Psaroulaki A, Tselentis Y, Gikas A, 2014. Murine typhus in elderly patients: a prospective study of 49 patients. Scand J Infect Dis 46: 779–782.

20. Irons JV, Cox GW, 1946. An epidemiological investigation of typhus fever in Texas, 1943–1945. Tex State J Med 42: 814–818.

21. Silpapojakul K, Mitarnun W, Ovartlarnporn B, Chamroonkul N, Khow-Ean U, 1996. Liver involvement in murine typhus. J Clin Microbiol 34: 228–232.

22. Biggs HM, Behravesh CB, Bradley KK, Dahlgren FS, Drexl NA, Dummer JS, Folk SM, Kato CY, Lash RR, Levin ML, Massung RF, Nadelman RB, Nicholson WL, Paddock CD, Pritt BS, Traeger MS, 2016. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis—United States. MMWR Morb Mortal Wkly Rep 65: 1–44.

23. Walker DH, Kirkman NH, 1980. Rocky Mountain spotted fever and deficiency in glucose-6-phosphate dehydrogenase. J Infect Dis 142: 771.

24. Raoult D, Leno D, Perrimont H, Gallais H, Walker DH, Casanova P, 1986. Haemolysis with Mediterranean spotted fever and glucose-6-phosphate dehydrogenase deficiency. Trans R Soc Trop Med Hyg 80: 961–962.

25. Pether JV, Jones W, Lloyd G, Rutter DA, Barry M, 1994. Fatal murine typhus from Spain. Lancet 344: 897–898.

26. CDC, 2009. Outbreak of Rickettsia typhi infection: Austin, Texas, 2008. MMWR Morb Mortal Wkly Rep 58: 1267–1270.

27. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

28. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

29. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

30. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

31. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

32. CDC, 2009. Outbreak of Rickettsia typhi infection: Austin, Texas, 2008. MMWR Morb Mortal Wkly Rep 58: 1267–1270.

33. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

34. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

35. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

36. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

37. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

38. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

39. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

40. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

41. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

42. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

43. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

44. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.

45. Walker DH, Kirkman HN, 1980. Rocky Mountain spotted fever and glucose-6-phosphate dehydrogenase deficiency. J Infect Dis 142: 771.